Clinical Pharmacokinetics of Atorvastatin

Clinical Pharmacokinetics

Volumn 42, Issue 13, 2003, Pages 1141-1160

  Lennernäs, Hans ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ATORVASTATIN; CERIVASTATIN; CIMETIDINE; CYCLOSPORIN; CYTOCHROME P450 3A4; DIGOXIN; DRUG METABOLITE; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; ITRACONAZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; MEVINOLIN; NELFINAVIR; PHENAZONE; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; SIMVASTATIN; STATINE DERIVATIVE; TACROLIMUS; TERFENADINE; TROGLITAZONE; UNINDEXED DRUG; VERAPAMIL;

ABDOMINAL DISCOMFORT; ACUTE KIDNEY FAILURE; AREA UNDER THE CURVE; ATHEROSCLEROSIS; BILE SECRETION; CHOLESTEROL BLOOD LEVEL; COMPARTMENT SYNDROME; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG OXIDATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; FIRST PASS EFFECT; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HEADACHE; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; LIVER DISEASE; MYOPATHY; NAUSEA; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS;

ADMINISTRATION, ORAL; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS; DRUG INTERACTIONS; FOOD-DRUG INTERACTIONS; GASTROINTESTINAL TRACT; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; PYRROLES;

EID: 0242383181     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342130-00005     Document Type: Review

References (103)

1. Superko HR, Krauss MR. Coronary artery disease regression: convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994; 90: 1056-69
2. Levine GN, Keaney Jr JF, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med 1995; 332: 512-21
3. Gotto AM. Lipid lowering, regression, and coronary events: a review of the interdisciplinary council on lipids and cardiovascular risk intervention, Seventh Council meeting. Circulation 1995; 92: 647-56
4. Brown BG, Zhao XQ, Sacco DE, et al. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781-91
5. Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
6. Shepherd J, Cobbe SM, Ford I, et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
7. Sacks FM, Pfeffer MA, Lemeul AM, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
8. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22
9. Vaughan CJ, Gotto Jr AM, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 1999; 35: 1-10
10. Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998; 80: 1-34
11. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413-28
12. Ni W, Egashira K, Kataoka C, et al. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res 2001 Aug 31; 89 (5): 415-21
13. Cilla Jr DD, Whitfield LR, Gibson DM, et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther 1996 Dec; 60 (6): 687-95
14. Lindahl A, Ungell A-L, Persson B, et al. Surface activity of fluvastatin and concentration dependent intestinal permeability in the rat. Pharm Res 1999; 16: 97-102
15. Kantola T, Krivistö KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998; 64: 58-65
16. Kearney AS, Crawford LF, Metha SC, et al. The interconversion kinetics, equilibrium and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981. Pharm Res 1993; 10: 1461-5
17. Ishigami M, Honda T, Takasaki W, et al. A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos 2001; 29: 282-8
18. Jacobsen W, Kuhn B, Soldner A, et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 2000; 28 (11): 1369-78
19. Prueksaritanont T, Subramanian R, Fang X, et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002; 30: 505-12
20. Posvar EL, Radulovic LL, Cilla DD, et al. Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. J Clin Pharmacol 1996; 36: 728-31
21. Radulovic LL, Cilla DD, Posvar EL, et al. Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol 1995; 35: 990-4
22. Shum YY, Huang N, Walter G, et al. Development, validation, and interlaboratory comparison of an HMG-CoA reductase inhibition assay for quantitation of atorvastatin in plasma matrices. Ther Drug Monit 1998; 20: 41-9
23. Gibson DM, Stern RH, Abel RB, et al. Absolute bioavailability of atorvastatin in man. Pharm Res 1997; 14: S253
24. Jemal M, Ouyang Z, Chen BC, et al. Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometry. Rapid Commun Mass Spectrom 1999; 13: 1003-15
25. Lennernäs H, Fager G. Clinical pharmacokinetics and pharmacodynamics of HMG-CoA reductase inhibitors: similarities and dissimilarities. Clin Pharmacokinet 1997; 35: 403-25
26. Malhotra HS, Goa KL. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs 2001; 61: 1835-81
27. Parker TS, McNamara DJ, Brown CD, et al. Plasma mevalonate as a measure of cholesterol synthesis in man. J Clin Invest 1984; 74: 795-804
28. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995 May; 15 (5): 678-82
29. Stern RH, Gibson DM, Whitfield LR. Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. Eur J Clin Pharmacol 1998; 53 (6): 475-8
30. Lea AP, McTavish D. Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 1997 May; 53 (5): 828-47
31. Stern RH, Yang BB, Hounslow NJ, et al. Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol 2000 Jun; 40 (6): 616-23
32. Guerin M, Lassel TS, Le Goff W, et al. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 2000 Jan; 20 (1): 189-97
33. Joukhadar C, Klein N, Prinz M, et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost 2001 Jan; 85 (1): 47-51
34. Amidon GL, Lennernäs H, Shah V, et al. Theoretical considerations in the correlation of drug product dissolution and in vivo bioavailability: a biopharmaceutical drug classification. Pharm Res 1995; 12: 413-20
35. Wu X, Whitfield LR, Stewart BH. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and proton-monocarboxylic acid co-transporter. Pharm Res 2000; 17: 209-15
36. Benet LZ, Cummins CL. The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev 2001 Oct 1; 50 Suppl. 1: S3-S11
37. Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001 Aug; 57 (5): 357-64
38. Boyd RA, Stern RH, Stewart BH, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein- mediated secretion. J Clin Pharmacol 2000 Jan; 40 (1): 91-8
39. Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997 Dec; 283 (3): 1552-62
40. Lennernäs H. Human jejunal effective permeability and its correlation to preclinical drug absorption models. J Pharm Pharmacol 1997; 49: 627-38
41. Winiwarter S, Bonham N, Hallberg A, et al. Correlation of human jejunal permeability (in vivo) with experimentally and theoretically derived parameters: a multivariate data analysis approach. J Med Chem 1999; 41: 4939-49
42. Lindahl A, Sandström R, Ungell A-L, et al. Jejunal permeability and hepatic extraction of fluvastatin in humans. J Clin Pharm Ther 1996; 60: 493-503
43. Stern RH, Yang BB, Horton M, et al. Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. J Clin Pharmacol 1997 Sep; 37 (9): 816-9
44. Lin JH, Chiba M, Baillie TA. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 1999 Jun; 51 (2): 135-58
45. Black AE, Hayes RN, Roth BD, et al. Metabolism and excretion of atorvastatin in rats and dogs. Drug Metab Dispos 1999 Aug; 27 (8): 916-23
46. Lennernäs H, Regårdh CG. Dose-dependent intestinal absorption and significant intestinal excretion (exsorption) of the beta-blocker pafenolol in the rat. Pharm Res 1993; 5: 727-31
47. Gramatte T, Oertel R. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin Pharmacol Ther 1999 Sep; 66 (3): 239-45
48. Fagerholm U, Johansson M. Lennernäs H. The correlation between rat and human small intestinal permeability to drugs with different physico-chemical properties. Pharm Res 1996; 13: 1335-41
49. Chiou WL, Jeong HY, Chung SM, et al. Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm Res 2000 Feb; 17 (2): 135-40
50. Fojo AT, Ueda K, Slamon DJ, et al. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 1987; 84 (1): 265-9
51. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Ther 2002; 301: 1042-51
52. Strassburg CP, Kneip S, Topp J, et al. Polymorphic gene regulation and interindividual variation fo UDP-glucuronosyl-transferase activity in human small intestine. J Biol Chem 2000; 275: 36164-71
53. Wu CY, Benet LZ, Hebert MF, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995; 58 (5): 492-7
54. Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996; 60 (1): 14-24
55. Regardh CG, Edgar B, Olsson R, et al. Pharmacokinetics of felodipine in patients with liver disease. Eur J Clin Pharmacol 1989; 36 (5): 473-9
56. Fromm MF, Busse D, Kroemer HK, et al. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 1996; 24 (4): 796-801
57. Sandström R, Knutson L, Knutson T, et al. The effect of ketoconazole on jejunal permeability and CYP 3A4 metabolism of R/S-verapamil in humans. Br J Clin Pharmacol 1999; 48: 180-9
58. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 1999 Aug; 66 (2): 118-27
59. Mazzu AL, Lasseter KC, Shamblen EC, et al. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000 Oct; 68 (4): 391-400
60. 14C atorvastatin in patients with T-tube drainage [abstract]. Proc Aust Soc Clin Exp Pharmacol Toxicol 1996; 3: 153
61. Li L, Meier PJ, Ballatori N. Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione. Mol Pharmacol 2002; 58: 335-40
62. Rolan PE. Plasma protein binding displacement interactions - why are they still regarded as clinically important? Br J Clin Pharmacol 1994; 37: 125-8
63. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30
64. Yang BB, Smithers JA, Stern RH, Sedman AJ, Olsen SC. Pharmacokinetics and dose proportionality of atorvastatin and its active metabolites [abstract]. Pharm Res 1996; 13 Suppl 1: S437
65. Ozdemir V, Kalowa W, Tang BK, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000 Jul; 10 (5): 373-88
66. Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002; 30: 1280-7
67. Hsiang B, Zhut Y, Wang Z, et al. A novel human hepatic organic anion transporting polypeptide (OATP 2). J Biol Chem 1999; 274: 37161-8
68. Nakai D, Nakagomi R, Furuta Y, et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharm Exp Pharmacol 2001; 297: 861-7
69. Brown CDA, Windass A, Bleasby K, et al. Rosuvastatin is a high affinity substrate of hepatic organic anion transport OATP-C [abstract]. Artherosclerosis 2001; 2 Suppl. 2: 90
70. Gibson DM, Bron NJ, Richens A, et al. Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol 1996; 36: 242-6
71. Cummins CL, Wu CH, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharm Ther 2002; 72: 474-89
72. Cilla Jr DD, Gibson DM, Whitfield LR, et al. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol 1996 Jul; 36 (7): 604-9
73. Lins RL, Matthys KE, Verpooten GA, et al. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrol Dial Transplant 2003; 18 (5): 967-76
74. Dowling TC, Briglia AE, Fink JC, et al. Characterisation of hepatic cytochrome P450 3A activity in patients with end stage renal disease. Clin Pharmacol Ther 2003; 73: 427-34
75. Whitfield LR, Stern RH, Sedman AJ, Abel R, Gibson DM. Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase. Eur J Drug Metab Pharmacokinet 2000 Apr-Jun; 25 (2): 97-101
76. Fleisher D, Li C, Zhou Y, et al. Drug, meal and formulation interactions influencing drug absorption after oral administration: clinical implications. Clin Pharmacokinet 1999 Mar; 36 (3): 233-54
77. Beaird SL. HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. J Am Pharm Assoc 2000; 40 (5): 637-44
78. Bogman K, Peyer AK, Torok M, et al. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001 Mar; 132 (6): 1183-92
79. Wang E, Casciano CN, Clement RP, et al. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res 2001 Jun; 18 (6): 800-6
80. McDonnell CG, Harte S, O'Driscoll J, et al. The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam. Anaesthesia 2003; 58: 899-904
81. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001 Sep; 35 (9): 1096-107
82. Maltz HC, Balog DL, Cheigh JS. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann Pharmacother 1999 Nov; 33 (11): 1176-9
83. Heerey A, Barry M, Ryan M, Kelly A. The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci 2000 Jul-Sep; 169 (3): 176-9
84. McManus BM, Horley KJ, Wilson JE, et al. Prominence of coronary arterial wall lipids in human heart allografts: implications for pathogenesis of allograft arteriopathy. Am J Pathol 1995 Aug; 147 (2): 293-308
85. Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use: report of two cases in cardiac transplant recipients. JAMA 1988 Jul 8; 260 (2): 239-41
86. Kusus M, Stapleton DD, Lertora JJ, et al. Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions. Am J Med Sci 2000 Dec; 320 (6): 394-7
87. Kobashigawa JA, Moriguchi JD, Ro TK, et al. Atorvastatin for refractory hypercholesterolemia in heart transplant patients [abstract]. J Am Coll Cardiol 1998; 31 Suppl. A: 157A
88. Wenisch C, Krause R, Fladerer P, et al. Acute rhabdomyolysis after atorvastatin and fusidic acid therapy. Am J Med 2000 Jul; 109 (1): 78
89. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001; 35: 908-17
90. Duell PB, Connor WE, Illingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol 1998 Feb 1; 81 (3): 368-9
91. Lill J, Bauer LA, Horn JR, et al. Cyclosporine-drug interactions and the influence of patient age. Am J Health Syst Pharm 2000 Sep 1; 57 (17): 1579-84
92. Hsyu PH, Schultz-Smith MD, Lillibridge JH, et al. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001 Dec; 45 (12): 3445-50
93. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG study A5047. AIDS 2002; 16: 569-77
94. Acosta EP. Pharmacokinetic enhancement of protease inhibitors. J Acquir Immune Defic Syndr 2002; 29: S11-8
95. DiTusa L, Luzier AB. Potential interaction between troglitazone and atorvastatin. J Clin Pharm Ther 2000 Aug; 25 (4): 279-82
96. Xie W, Yeuh MF, Radominska-Pandya A, et al. Control of steroid, heme, and cacinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc Natl Acad Sci U S A 2003; 100: 4150-5
97. Loi CM, Stern RH, Abel R, et al. Effect of troglitazone on pharmacokinetics and pharmacodynamics of atorvastatin [abstract]. Clin Pharmacol Ther 1999; 65: 186
98. Siedlik PH, Olson SC, Yang BB, et al. Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol 1999 May; 39 (5): 501-4
99. Yang BB, Hounslow NJ, Sedman AJ, et al. Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of amipyrine. J Clin Pharmacol 1996 Apr; 36 (4): 356-60
100. Renders L, Mayer-Kadner I, Koch C, et al. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. Nephrol Dial Transplant 2001 Jan; 16 (1): 141-6
101. Stern RH, Smithers JA, Olson SC. Atorvastatin does not produce a clinically significant effect on the pharmacokinetics of terfenadine. J Clin Pharmacol 1998 Aug; 38 (8): 753-7
102. Cohen LH, van Leeuwen RE, van Thiel GC, et al. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos 2000 Dec; 21 (9): 353-64
103. Hamman MA, Bruce MA, Haehner-Daniels BD, et al. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 2001 Mar; 69 (3): 114-21